Prevent Blindness declares August Children’s Eye Health and Safety Month

As the school year begins, Prevent Blindness announced in a press release that it will provide resources for parents and caregivers in honor of Children’s Eye Health and Safety Month.

Free resources include factsheets, media graphics, toolkits, webpages, and a series of expert interviews on a variety of eye health topics such as myopia, amblyopia, strabismus, digital screen time, and vision testing. is included.

“For 115 years, we have made it our mission to make sure children get the eye care they need,” said Prevent Blindness President and CEO. Jeff Todd said in a release. “By working as a team with parents, program partners and allied health care professionals, we are helping children take the first steps toward maintaining healthy vision for life.”

Over the past few months, Healio has been reporting the latest research and news in children’s eye care. Popular articles include:

Atropine infusion fails to slow myopia in U.S. children, study finds

In a randomized clinical trial, nightly atropine instillation for 2 years in a US pediatric cohort did not slow myopia progression or axial elongation compared with placebo.

This result is inconsistent with previous studies in Asian populations, and further studies are needed to assess genetic factors, higher atropine doses, and many other variables. Michael X. Lepka, MD, MBA, Vice President of Clinical Practice at the Wilmer Eye Institute and Professor of Ophthalmology at Johns Hopkins University write: JAMA Ophthalmology. read more.

Essilor Stellest spectacle lenses slow progression of myopic axial length in children

EssilorLuxottica’s Essilor Stellest lenses slowed the progression of myopia and the increase in axial length in children in a four-year clinical trial, according to data presented at the Society for Vision and Ophthalmology Research Conference.

The trial, which began in 2018 at China’s Wenzhou Medical University Eye Hospital, found that children wearing glasses with highly aspheric lenses could reduce myopia of 1.25D or more over four years, according to a company press release. It is said that HAL lenses were the inspiration for the optical design of the Essilor Stellest lenses. read more.

Euclid ortho-K lenses are effective as ‘one of the most widely studied lenses’ for myopia in children

According to a study published in , unparalleled extensive literature supports the effectiveness of Euclidean Emerald orthokeratology lenses in slowing axial elongation in myopic children. contact lens and anterior segment.

“The first Euclid orthokeratology lens was approved by the FDA 20 years ago. I thought it would be a great opportunity to discuss.” mark a. Brimore, MCOptom, PhD, FAAO, Adjunct Professor of Optometry at the University of Houston said in a related press release from Euclid. “Comprehensive data on other lens designs are difficult to come by, but Euclid’s lens is one of the most extensively studied orthokeratology his lenses, and this provides a rich data set.” You get it.” Read more.

Similar risk of corneal adverse events in children and adults wearing soft contacts

review of the literature found that the incidence of microbial keratitis in children wearing soft contact lenses is not higher than that reported in adults, but the incidence of corneal infiltration events is lower. eye and contact lens.

“Historically, ophthalmology has been concerned about the safety of putting contact lenses in children.” Mark A. Brimore Dr. MCO Ptom, and Katherine Richdale, OD, PhD, Both of the University of Houston Department of Optometry wrote: “Of particular concern was that the risk of microbial keratitis may not outweigh the improved quality of life and other perceived benefits provided by contact lens wear.” I Read.

FDA Accepts NDA for Low-Dose Atropine Eye Drops for Pediatric Myopia Treatment

Vyluma Inc. announced that the FDA will review its new drug application for NVK002, a preservative-free low-dose atropine eye drop for myopia in children ages 3 to 17 years.

“The FDA approval of our NDA is a major milestone for Vyluma and brings us another step closer to advancing NVK002 as a new first-in-class treatment option for myopic children.” Dr. Navneet Puri, Vyluma’s founder and chairman said in the company’s press release: “NVK002 has been rigorously tested clinically and adheres to the high quality standards expected of a pharmaceutical manufactured product. I look forward to it.” Read more.